Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.50 |
| ▸ | PDE4A | P27815 | 6/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425304 | 0.85 | PDE4B (0.56) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL26425447 | 0.83 | PDE4B (0.50) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL26425445 | 0.83 | PDE4B (0.50) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL26425326 | 0.83 | NFE2L2 (0.50) | CA1CA2PDE3ANFE2L2PTGS1 | |
| SCHEMBL26425450 | 0.83 | PDE4B (0.53) | CA1CA2PDE3ANFE2L2PDE4A | |
| SCHEMBL26425553 | 0.81 | PDE4B (0.54) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL26425448 | 0.80 | PDE4B (0.56) | CA1CA2PDE3ANFE2L2PDE4A | |
| SCHEMBL26425601 | 0.80 | PDE4B (0.62) | CA1CA2PDE3APDE4APDE4B | |
| Tavaborole SCHEMBL29372574 | 0.78 | CA1 (1.00) | CA1CA2PDE3APDE4APDE4B | |
| SCHEMBL19171231 | 0.78 | CA1 (1.00) | CA1CA2PDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-4132657-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | The George Washington University (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-111333672-B | Sterol regulatory element binding protein and acidic nucleoplasm DNA binding protein-1 inhibitor, and preparation method and application thereof | 中国医学科学院放射医学研究所 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | TP53, ANXA5, MCL1 | CA1 807/4885CA2 1102/4885PDE3A 2291/4885 |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | CA1 807/4885CA2 1102/4885PDE3A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.